NVRO continues to gain due to its business expansion into the SI joint fusion market and optimistic 2024 results amid a weak SCS market.

Op dinsdag handhaafden analisten van Stifel hun koopadvies en koersdoel van $ 94,00 voor aandelen van Globus Medical (NYSE:GMED), met focus op de fusierichtlijnen en potentiële winst per aandeel (EPS) ...

Nevro Corp. (NYSE:NVRO – Get Free Report) has earned a consensus rating of “Reduce” from the thirteen research firms that are covering the company, Marketbeat reports. Two analysts have rated the ...

Nevro Corp. NVRO reported a loss per share of 64 cents in the fourth quarter of 2024, wider than the year-ago quarter’s loss of 15 cents. The Zacks Consensus Estimate is pegged at a loss per share of ...

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Alpha Teknova (TKNO – Research Report), Wave Life Sciences ...

Nevro (NVRO) came out with a quarterly loss of $0.64 per share versus the Zacks Consensus Estimate of a loss of $0.79. This compares to loss of $0.15 per share a year ago. These figures are adjusted ...

The Redwood City, California-based company said it had a loss of $1.41 per share. Losses, adjusted for one-time gains and costs, came to 64 cents per share. The results surpassed Wall Street ...

Management uses certain non-GAAP financial measures, most specifically adjusted EBITDA, as a supplement to GAAP financial measures to further evaluate the Company's operating performance period ...